CheckMate914

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Followin

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

옵디보, '신세포암'에서 희비 교차 < 암/혈액/희귀/소아청소년 < 암/혈액/희귀/소아청소년 < 학술 < 기사본문 - 메디칼업저버

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials - ScienceDirect

Adjuvant immunotherapy does not improve DFS in renal cancer

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

CheckMate914

Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments

Nivolumab Alone, Plus Ipilimumab Being Tested in Early-Stage, High-Risk RCC

Perioperative immunotherapy for renal cell carcinoma: looking beyond the data

日本がん対策図鑑 【腎細胞がん：術後治療（DFS）】「オプジーボ＋ヤーボイ」vs「経過観察」

SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status